Business · 16/04/2026Updated: 10/16/2026 · 1 min read
FDA Approves Respiratory Syncytial Virus Vaccine Under Priority Review Voucher
Summary
The FDA has approved MRESVIA (Respiratory Syncytial Virus Vaccine), a material threat medical countermeasure, after determining it meets the redemption criteria for a priority review voucher.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →